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Diabetic Retinopathy in 2011: Further
Insights From New Epidemiological
Studies and Clinical Trials
D
iabetic retinopathy (DR) is a com-
mon and speciﬁcm i c r o v a s c u l a r
complication of diabetes and one
oftheleadingglobalcausesofpreventable
blindness. Population-based studies sug-
gest that about one-third of the diabetic
population have signs of DR and approx-
imately one-tenth have vision-threatening
stages of retinopathy, such as diabetic
macular edema and proliferative retinopa-
thy(1,2). Notwithstanding its effectsonvi-
sion, DR is costly (3), substantially impacts
on the patient’s quality of life (4), and is
linkedwithagreaterriskoflife-threatening
systemic vascular complications (5).
Because blindness from DR is pre-
ventable from both public health screen-
ing and clinical management perspectives,
it is important to precisely identify per-
sons at risk for developing DR and those
most likely to progress to severe vision-
threateningstages. Inthis issueof Diabetes
Care,Zavrelovaetal.(6)presentafascinat-
ing and informative article that discusses
people with diabetes having distinct de-
velopmental patterns of DR and that there
maybespeciﬁcriskfactorsassociatedwith
different patterns of progression. From a
large group of patients with type 2 diabe-
tes(N53,343),theauthorsidentiﬁedﬁve
clusters of developmental patterns of DR.
The largest (cluster A) included patients
who did not develop any form of DR
over a 6-year period (“persistent no reti-
nopathy”). Cluster B included patients
with a high probability of a mild form of
DR,whichdisappearedovertimeandthus
are not at risk for vision loss. Two pro-
gressive clusters (C and D) were identiﬁed
and differed from each other in severity
and in speed of developing retinopathy.
Finally, a ﬁfth cluster (E) consisted of pa-
tients who hadpersistent proliferative DR,
including previous laser treatment.
Perhaps the most important ﬁnding
was that almost 90% of this population
(cluster A) were considered to have “per-
sistent no retinopathy” after 6 years. Fur-
thermore, there was another 4.9% of
people (cluster B) with mild DR and signs
of a “slow regression” of retinopathy over
time. Thus, in total, nearly 94% of people
with type 2 diabetes are not at risk for
developing vision-threatening retinopa-
thy. Contemporary population-based
longitudinal data for DR are scarce al-
though prospective data from the Wis-
consin Epidemiologic Study of Diabetic
Retinopathy (WESDR) in the U.S. have
shown a reduction in the annualized in-
cidence and progression of DR in type 1
patients in recent years (7,8). Thus, the
phenomenon observed in the study by
Zavrelova et al. is supported by WESDR
data and could reﬂect effective screening
and improvements in the control of sys-
temic risk factors in diabetes care in the
last two decades (9–12). Further work is
clearlyneededtoestablishwhetherdiabetes
care is indeed having a positive and sus-
tained inﬂuence on diabetes complications
as it would reinforce the impact and effec-
tiveness of substantial public health efforts
in tackling diabetes around the world.
Glycemic control remains the foun-
dation for diabetes care. Consistent with
l a n d m a r ks t u d i e ss u c ha st h eD i a b e t e s
Control and Complications Trial (DCCT)
and the UK Prospective Diabetes Study
(UKPDS), which have provided strong
evidence of the beneﬁts of good glycemic
control in reducing the risk of develop-
ment and progression of DR in both type
1 and type 2 diabetes (13,14), Zavrelova
et al. report that patients in the two non-
progressive clusters had lower mean values
of HbA1c than patients in the progressive
clusters C, D,and E over time. These ﬁnd-
ings also support recent data from the
Action to Control Cardiovascular Risk in
Diabetes (ACCORD) Eye trial, which
found a signiﬁcant difference in three-
step progression of DR between those
with intense glycemic control compared
with those with standard care (15).
Interestingly, total cholesterol was also
consistently lower in the nonprogressive
group (clusters A and B) compared with
the progressive groups (clusters C and D)
suggesting a role of lipids in the develop-
mental patterns of DR. Previous studies
have reported dyslipidemia as a factor in
the pathogenesis of DR, but major clinical
trials showing the effect of lipid lowering
onDRprogressionhavenotbeenconclusive
( 1 6 ) .I nt h el a s t3y e a r s ,h o w e v e r ,t w o
major randomized trials, the Fenoﬁbrate
Intervention and Event Lowering in Dia-
betes (FIELD) and the ACCORD Eye
trials, have ﬁrmly demonstrated that
fenoﬁbrate may play an important role
in decreasing the progression of DR. The
ACCORDEyetrial,whichcomparedfeno-
ﬁbrate with placebo in patients on statins,
conﬁrmed the superiority of fenoﬁbrate
in preventing the progression of DR with
a risk reduction similar to that of FIELD
(30–40%) (17). However, because this
effect was not associated with a signiﬁcant
reduction in serum cholesterol levels, fur-
ther studies are needed to better under-
stand the mechanisms underpinning the
effectoffenoﬁbrate(17).Therearesugges-
tions that fenoﬁbrate may have effects on
nonlipid pathways such as inﬂammation,
endothelial function, and vascular endo-
thelial growth factor (18).
Zavrelova et al. also conﬁrm the
importance of blood pressure control on
the developmental patterns of DR in this
sample. In their article, systolic blood
pressure (sBP) control appears to play a
more important role than diastolic blood
pressure, with the two progressive clusters
(C and D) correlated with periods of de-
terioration in sBP ranging between 10–15
mmHg in these two groups. In contrast,
at no time during the follow-up was there
an increase in sBP exceeding 5 mmHg in
clusters A and B. These ﬁndings indicate
that large increments in sBP may impact
on the progression of DR in type 2 pa-
tients, and they conﬁrm previous reports
that for each 10-mmHg increase in sBP,
there is an approximately 10% excess risk
of early DR and a 15% excess risk of pro-
liferative retinopathy (19,20).
Data from new clinical trials, how-
ever, suggest that there is a limit to the
effectiveness of blood pressure control in
preventing DR. In contrast to the UKPDS,
both the Action in Diabetes and Vascu-
lar Disease (ADVANCE) study and the
ACCORD Eye trial did not ﬁnd intensive
blood pressure control to be useful in
reducing the progression of DR. This
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EDITORIAL (SEE ZAVRELOVA ET AL., P. 867)could be related to a short follow-up time
in the ACCORD Eye trial (;5 years) com-
pared with the 20-year follow-up of the
UKPDS, where tighter blood pressure
control reduced the risks of retinopathy
progression by about one-third, visual
loss by one-half, and the need for laser
treatment by one-third in people with
type 2 diabetes (21,22). It is also possible
that the aggressive lower blood pressure
targets set by the ACCORD Eye trial, i.e.,
sBP ,120 mmHg (compared with ,150
m m H gi nt h eU K P D S ) ,m a yi n d i c a t ea
ﬂoor effect to the beneﬁts of lowering
blood pressure below normal ranges (17).
While the article by Zavrelova et al.
(6) shows distinct developmental pat-
terns of DR and associated speciﬁcr i s k
factors, it has some shortcomings that fu-
ture studies should focus on. The most
signiﬁcant one is a lack of information
associated with the proﬁle of each cluster
that could lead to the optimization of
treatment by targeting different patient
groups. An understanding of the role of
the duration of diabetes across these clus-
ters isalso lacking and needstode further
investigated. From a public health per-
spective, improving our understanding
of who is unlikely to progress (or even
likely to regress) has economic and clinical
implicationsondifferentialpossiblescreen-
ing intervals in selected patients. Such pa-
tients, for example, could be screened
yearly for 2 or even 3 times. Conversely,
those at higher risk of progression require
morefrequentmonitoring.Anotherimpor-
tantareaoffutureresearchistounderstand
whetherpatientscanchangefromoneclus-
ter to another. For example, it would be
interesting to investigate whether these
data could be used to help patients who
are likely “progressors” to improve their
glucose management. Future work inves-
tigating these limitations would have sig-
niﬁcant implications and extend on the
ﬁndings reported by Zavrelova et al.
In conclusion, considering the cur-
rent high prevalence estimates of DR and
vision-threateningDRandtheanticipated
tripling of the number of people world-
wide to develop type 2 diabetes by 2040
(23), the ﬁnding that over 90% of that
population are not at risk for developing
severe DRintheshorttermisquiteprom-
ising.Alongerfollow-upperiod(.15–20
years with regular eye examinations) for
these patients is therefore warranted to
ascertain if this phenomenon persists
longitudinally, and what risk factors are
associated with progression if it is evident;
inform patients about the progression of
DR in the three progressive clusters; and
ﬁnally, optimize these data to better in-
form patients of the public health initia-
tives and clinical practices.
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